Fig. 8From: METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysisGSEA for comparing KEGG pathways and HALLMARK terms between the low and high METTL7B groups. A Twenty-nine KEGG pathways were significantly enriched in the high METTL7B group. B The top 10 enriched HALLMARK terms in the high METTL7B groupBack to article page